NCT03371485View on ClinicalTrials.gov

AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

May 29, 2018

Primary Completion Date

August 8, 2022

Study Completion Date

August 8, 2022

Conditions

Advanced Non-small Cell Lung Cancer

Interventions

BIOLOGICAL

AST-VAC2

Allogeneic dendritic cell vaccine.

Trial Locations (2)

Unknown

Queen Elizabeth Hospital, Birmingham

Southampton General Hospital, Southampton

Sponsors

Lead Sponsor

Cancer Research UK

All Listed Sponsors

lead

Cancer Research UK

OTHER